Loading clinical trials...
Loading clinical trials...
Substance P-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial
Substance P is a neuropeptide implicated in the pathogenesis of headache. This study investigates whether its administration can trigger migraine attacks in individuals with migraine without aura.
Substance P is a vasoactive neuropeptide of the tachykinin family, expressed in various cell types, including primary afferents of the trigeminal ganglion that innervate the meninges and associated vasculature. Its most well-established role is in nociceptive signaling, and accumulating evidence implicates substance P in the pathogenesis of headache. This study investigates whether intravenous infusion of substance P can induce migraine attacks in individuals with a history of migraine without aura. To test this, the investigators will conduct a randomized, double-blind, placebo-controlled, two-way crossover trial.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Start Date
May 13, 2025
Primary Completion Date
May 1, 2026
Completion Date
December 1, 2026
Last Updated
June 5, 2025
21
ESTIMATED participants
Substance P
DRUG
Placebo
DRUG
Lead Sponsor
Danish Headache Center
NCT07018713
NCT06641466
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions